SCHEMBL2934898

SCHEMBL2934898

CC(C)C[CH]NC(=O)[C@@H](NC(=O)c1ccc(-c2ccccc2)cn1)[C@@H](C)O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSA P10619 1/20 0.47
HIF1A Q16665 6/20 0.44
ELANE P08246 1/20 0.44
CTSG P08311 1/20 0.44
CYP3A4 P08684 1/20 0.44
PSMB1 P20618 1/20 0.44
CMA1 P23946 1/20 0.44
PSMB8 P28062 1/20 0.44
PSMB9 P28065 1/20 0.44
PSMB5 P28074 1/20 0.44
PSMB10 P40306 1/20 0.44
PSMB2 P49721 1/20 0.44
MME P08473 2/20 0.40
EGLN1 Q9GZT9 2/20 0.40
USP30 Q70CQ3 1/20 0.38
DGAT1 O75907 2/20 0.37
CNR1 P21554 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2933374 0.86 PSMB5 (0.48) CTSAELANECTSGCYP3A4PSMB1
SCHEMBL2931761 0.85 CTSA (0.47) CTSAELANECTSGCYP3A4PSMB1
SCHEMBL610095 0.84 NPC1 (0.52)
SCHEMBL2934925 0.83 KDM4E (0.47) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2934901 0.82 NPC1 (0.51) CTSAHIF1AELANECTSGCYP3A4
SCHEMBL2932636 0.82 EGLN1 (0.41) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2927875 0.81 ELANE (0.47) CTSAELANECTSGCYP3A4PSMB1
SCHEMBL2932157 0.81 PSMB5 (0.52) CTSAELANECTSGCYP3A4PSMB1
SCHEMBL608032 0.81 ELANE (0.67) CTSAELANECTSGCYP3A4PSMB1
SCHEMBL619140 0.80 HDAC8 (0.45) ELANECTSGCYP3A4PSMB1CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 CTSA 209/4885HIF1A 1955/4885ELANE 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.